A questionnaire survey on the use of quick-acting insulin analog in Japanese children and adoloscents with type 1 diabetes

Pediatrics International

Volumn 46, Issue 3, 2004, Pages 285-290

  Urakami, Tatsuhiko ^a   Kawamura, Tomoyuki ^b   Sugihara, Shigetaka ^c   Miyamoto, Shigeki ^d   Amemiya, Shin ^e   Sasaki, Nozomu ^f   Matsuura, Nobuo ^g  

^a NIHON UNIVERSITY   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^d CHIBA CHILDREN'S HOSPITAL   (Japan)

^e UNIVERSITY OF YAMANASHI   (Japan)

^f SAITAMA MEDICAL UNIVERSITY   (Japan)

^g KITASATO UNIVERSITY   (Japan)

Author keywords

Glycemic control; Quality of life; Questionnaire survey; Quick acting insulin analog; Type 1 diabetes

Indexed keywords

INSULIN DERIVATIVE; INSULIN LISPRO; NOVO RAPID; UNCLASSIFIED DRUG;

ADOLESCENCE; ADOLESCENT; CONTROLLED STUDY; DOSE RESPONSE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; JAPAN; LIFESTYLE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW;

ADOLESCENT; CHILD; DATA COLLECTION; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; JAPAN; LIFE STYLE; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 2942598498     PISSN: 13288067     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-200x.2004.01891.x     Document Type: Review

References (20)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993; 329: 977-86.
2. White NH, Cleary PA, Dahms W, Goldstein D, Malone J, Tamborlane WV. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J. Pediatr. 2001; 139: 804-12.
3. Alsaeid M, Qabazard M, Shaltout A, Sharma PN. Impact of glycemic control on serum lipoprotein (a) in Arab children with type 1 diabetes. Pediatr. Int. 2001; 43: 246-50.
4. Ebeling P, Jansson PA, Smith U, Lalli C, Bolli GB, Koivisto VA. Strategies toward improved control during insulin lispro therapy in IDDM. Importance of basal insulin. Diabetes Care 1997; 20: 1287-9.
5. Del Sindaco P, Ciofetta M, Lalli C et al. Use of the short-acting insulin analogue lispro in intensive treatment of type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection-meal. Diabet. Med. 1998; 15: 592-600.
6. Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 2000; 223: 583-8.
7. Home PD, Lindholm A, Rust A for the European Insulin Aspart Study Group. Insulin Aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial. Diabet. Med. 2000; 17: 762-70.
8. Anderson JH Jr, Brunelle RL, Koivisto VA et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. Diabetes 1997; 46: 265-70.
9. Anderson JH Jr, Brunelle RL, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R. Improved mealtime treatment of diabetes mellitus using an insulin analogue. Multicenter Insulin Lispro Study Group. Clin. Ther. 1997; 19: 62-72.
10. Garg SK, Carmain JA, Braddy KC, Anderson JH, Vignati L, Jennings MK, Chase HP. Pre-meal insulin analogue insulin lispro vs Humulin R insulin treatment in young subjects with type 1 diabetes. Diabet. Med. 1996; 13: 47-52.
11. Matsuura N, Niimi H, Isshiki G, Uchigata Y. An evaluation of multiple injection therapy with insulin lispro in Japanese pediatric patients with type 1 diabetes. J. Clin. Therap. Med. 2000; 16: 1665-76 (in Japanese).
12. Mohn A, Matyka KA, Harris DA, Ross KM, Edge JA, Dunger DB. Lispro or regular insulin for multiple injection therapy in adolescence. Differences in free insulin and glucose levels overnight. Diabetes Care 1999; 22: 27-32.
13. Mortensen HB, Lindholm A, Olsen BS, Hylleberg B. Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes. Eur. J. Pediatr. 2000; 159: 483-8.
14. Rutledge KS, Chase HP, Klingensmith GJ, Walravens PA, Slover RH, Garg SK. Effectiveness of postprandial Humalog in toddlers with diabetes. Pediatrics 1997; 100: 968-72.
15. Garcia L, Lamas C, Tuset MJ, Alonso M, Barrio R. Treatment with the insulin analogue lispro in children and adolescents with type 1 diabetes mellitus: evaluation over a 3-year period. Diabetes Nutr. Metab. 2002; 15: 7-13.
16. The Japanese Study Group of Insulin Therapy for Childhood and Adolescent Diabetes (JSGIT). Initial aims and impact of the family history of type 1 diabetes mellitus in Japanese children. Pediatr. Diabetes 2001; 2: 160-9.
17. Dimitriadis GD, Gerich JE. Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus. Diabetes Care 1983; 6: 374-7.
18. Jorgensen LN, Nielsen FS. Timing of pre-meal insulins in diabetic patients on a multiple daily injection regimen. A questionnaire study. Diabetologia 1990; 33: A116.
19. Kuzuya T, Kosaka K, Akanuma Y et al. Comparison of insulin lyspro and regular human insulin in multiple injection therapy in patients with type 1 and type 2 diabetes in Japan. J. Clin. Therap. Med. 2000; 16: 1613-530 (in Japanese).
20. Iwamoto Y, Akanuma Y, Niimi H et al. Comparison between insulin aspart and soluble human insulin in type 1 diabetes (IDDM) patients with Basal-Bolus insulin therapy-Phase III clinical trial in Japan. J. Jpn. Diab. Soc. 2001; 44: 799-811 (in Japanese).